Use of neuroendocrine hormones to promote reconstitution after bone marrow transplantation

NeuroImmunoModulation

Volumn 6, Issue 1-2, 1999, Pages 69-80

  Woody, Mary A ^a   Welniak, Lisbeth A ^b   Richards, Susan ^b   Taub, Dennis D ^c   Tian, Zhi Gang ^d   Sun, Rui ^d   Longo, Dan L ^c   Murphy, William J ^a,e  

^a NATIONAL CANCER INSTITUTE   (United States)

^b GENZYME CORPORATION   (United States)

^c NATIONAL INSTITUTE ON AGING   (United States)

^d SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG FIRST MEDICAL UNIVERSITY   (China)

^e SAIC FREDERICK INC   (United States)

Author keywords

Growth hormone; Hematopoiesis; Immune parameters; Prolactin; Transplantation

Indexed keywords

GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GROWTH HORMONE; INTERLEUKIN 2; PROLACTIN;

ANIMAL CELL; ARTICLE; BONE MARROW TRANSPLANTATION; GRAFT VERSUS HOST REACTION; HEMATOPOIESIS; HEMATOPOIETIC CELL; HORMONAL REGULATION; HORMONE ACTION; MEMBRANE RECONSTITUTION; NEUROENDOCRINE SYSTEM; NONHUMAN; OPPORTUNISTIC INFECTION; PLEIOTROPY; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; WEIGHT GAIN;

ANIMALS; BONE MARROW TRANSPLANTATION; GROWTH HORMONE; HEMATOPOIESIS; HUMANS; IMMUNE SYSTEM; PROLACTIN; T-LYMPHOCYTES;

EID: 0033006925     PISSN: 10217401     EISSN: None     Source Type: Journal    
DOI: 10.1159/000026366     Document Type: Article

References (101)

1. Murphy W, Longo D: The potential role of NK cells in the separation of graft-versus-tumor effects from graft-versus-host disease after allogeneic bone marrow transplantation. Immunol Rev 1997;157:167-176.
2. Bazan J: Haemopoietic receptors and helical cytokines. Immunol Today 1990;11:350-354.
3. Gouilleux F, Pallard C, Dusanter-Fourt I, Wakao H, Haldosen L, Norstedt D, Groner B: Prolactin, growth hormone, erythropoietin and granulocte-macrophage colony stimulating factor induce MGF-Stat5 DNA binding activity. EMBO J 1995; 14:2005-2013.
4. Pellegrini I, Lebrun J, Ali S, Kelly P: Expression of prolactin and its receptor in human lymphoid cells. Mol Endocrinol 1992;6:1023-1031.
5. Bellone G, Geuna M, Carbone A, Silvestri S, Foa R, Emaneulli G, Matera L: Regulatory action of prolactin on the in vitro growth of CD34+ve human hemopoietic progenitor cells. J Cell Physiol 1995;163:221-231.
6. Gagnerault M-C, Postel-Vinay M, Dardenne M: Expression of growth hormone receptors in murine lymphoid cells analyzed by flow cytofluorometry. Endocrinology 1996;137:1719-1726.
7. Gala R: Prolactin and growth hormone in the regulation of the immune system. Proc Soc Exp Biol Med 1991;198:513-527.
8. Kooijman R, Malur A, Van Buul-Offers S, Hooghe-Peters E: Growth hormone expression in murine bone marrow cells is independent of the pituitary transcription factor pit-1. Endocrinology 1997;138:3949-3955.
9. Delhase M, Vergani P, Malur A, Hooghe-Peters E, Hooghe R: The transcription factor pit-1/ghf-1 is expressed in hemopoietic and lymphoid tissues. Eur J Immunol 1993;23:951-955.
10. Gellersen B, Kempf R, Telgmann R, DiMattia G: Nonpituitary human prolactin gene transcription is independent of pit-1 and differentially controlled in lymphocytes and in endometrial stroma. Mol Endocrinol 1994;8:356-373.
11. Gala R: The influence of thyroxine, growth hormone and prolactin alone and in combination on the production of prolactin-like activity by splenocytes from Snell dwarf mice. Life Sci 1995;57:113-122.
12. Melen L, Hennen G, Dullaart R, Heinen E, Igout A: Both pituitary and placental growth hormone transcripts are expressed in human peripheral blood mononuclear cells. Clin Exp Immunol 1997;111:336-340.
13. Han V, D'Ercole A, Lund P: Cellular localization of somatomedin (insulin-like growth factor) messenger RNA in the human fetus. Science 1987;236:193-197.
14. Murphy W, Durum S, Anver M, Longo D: Immunologic and hematologic effects of neuroendocrine hormones. Studies on DW/J dwarf mice. J Immunol 1992;148:3799-3805.
15. Nagy E, Berczi I: Hypophysectomized rats depend on residual prolactin for survival. Endocrinology 1991;128:2776-2784.
16. Horseman N, Zhao W, Montecino-Rodriquez E, Tanaka M, Nakashima K, Engle S, Smith F, Markoff E, Dorshkind K: Defective mammopoiesis, but normal hematopoiesis, in mice with a targeted disruption of the prolactin gene. EMBO J 1997;16:6926-6935.
17. Baroni C, Fabris N, Bertoli G: Effects of hormones on development and function of lymphoid tissues. Synergistic action of thyroxin and somatotropic hormone in pituitary dwarf mice. Immunology 1969;17:303-314.
18. Montecino-Rodriquez E, Clark R, Johnson A, Collins L, Dorshkind K: Defective B cell development in Snell dwarf (dw/dw) mice can be corrected by thyroxine treatment. J Immunol 1996;157:3334-3340.
19. Kotzmann H, Riedl M, Clodi M, Barnas U, Kaider A, Hocker P, Luger A: The influence of growth hormone substitution therapy on erythroid and myeloid progenitor cells and on peripheral blood cells in adult patients with growth hormone deficiency. Eur J Clin Invest 1996;26:1175-1181.
20. Nagy E, Berczi I: Pituitary dependence of bone marrow function. Br J Haematol 1989;71:457-462.
21. Blazar B, Brennan C, Broxmeyer H, Shultz L, Vallera D: Transgenic mice expressing bovine growth hormone (bGH) or human GH releasing hormone (hGRH) have increased splenic progenitor cell colony formation and DNA synthesis in vitro and in vivo. Exp Hematol 1995; 23:1397-1406.
22. Tsarfaty G, Longo D, Murphy W: Human insulin-like growth factor I exerts hematopoietic growth-promoting effects after in vivo administration. Exp Hematol 1994;22:1273-1277.
23. Murphy W, Tsarfaty G, Longo D: Growth hormone exerts hematopoietic growth-promoting effects in vivo and partially counteracts the myelosuppressive effects of azidothymidine. Blood 1992;80:1443-1447.
24. Merchav S, Tatarsky I, Hochberg Z: Enhancement of human granulopoiesis in vitro by biosynthetic insulin-like growth factor I/somatomedin C and human growth hormone. J Clin Invest 1988;81:791-797.
25. Ratajczak M, Kuczynski W, Onodera K, Moore J, Ratajczak J, Kregenow D, DeRiel K, Gewirtz A: A reappraisal of the role of insulinlike growth factor I in the regulation of human hematopoiesis. J Clin Invest 1994;94:320-327.
26. Bellone G, Astarita P, Artusio E, Silvestri S, Mareschi K, Turletti A, Buttiglieri S, Emanuelli G, Matera L: Bone marrow stroma-derived prolactin is involved in basal and platelet-activating factor-stimulated in vitro erythropoiesis. Blood 1997;90:21-27.
27. Pierpaoli W, Sorkin E: Relationship between thymus and hypophysis. Nature 1967;215: 834-837.
28. Pierpaoli W, Sorkin E: Hormones and immunologic capacity. I. Effect of heterologous antigrowth hormone (ASTH) antiserum on thymus and peripheral lymphatic tissue in mice. Induction of a wasting syndrome. J Immunol 1968; 101:1036-1043.
29. Cross R, Markesbery W, Brooks W, Roszman T: Hypothalamic-immune interactions: Neuromodulation of natural killer activity by lesioning of the anterior hypothalamus. Immunology 1984;51:399-405.
30. Forni G, Bindoni M, Santoni A, Belluardo N, Marchese A, Giovarelli M: Radiofrequency destruction of the tuberoinfundibular region of the hypothalamus permanently abrogates NK cell activity in mice. Nature 1983;306:181-184.
31. Saxena Q, Saxena R, Adler W: Regulation of natural killer activity in vivo. III. Effect of hypophysectomy and growth hormone treatment on the natural killer activity of the mouse spleen cell population. Int Arch Allergy Appl Immunol 1982;67:169-174.
32. Berczi I, Nagy E, Kovacs K, Horvath E: Regulation of humoral immunity in rats by pituitary hormones. Acta Endocrinol (Copenh) 1981;98: 506-513.
33. Nagy E, Berczi I, Friesen H: Regulation of immunity in rats by lactogenic and growth hormones. Acta Endocrinol (Copenh) 1983;102: 351-357.
34. Voss J, Rosenfeld M: Anterior pituitary development: Short tales from dwarf mice. Cell 1992;70:527-530.
35. Pierpaoli W, Baroni C, Fabris N, Sorkin E: Hormones and immunological capacity. II. Reconstitution of antibody production in hormonally deficient mice by somatotropic hormone, thyrotropic hormone and thyroxin. Immunology 1969;16:217-230.
36. Baroni C: Thymus, peripheral lymphoid tissues and immunological responsiveness of the pituitary dwarf mouse. Experientia 1967;23:282-283.
37. Fabris N, Pierpaoli W, Sorkin E: Hormones and the immunological capacity. III. The immunodeficiency disease of the hypopituitary Snell-Bagg dwarf mouse. Clin Exp Immunol 1971;9:209-225.
38. Fabris N, Pierpaoli W, Sorkin E: Hormones and the immunological capacity. IV. Restorative effects of developmental hormones or of lymphocytes on the immunodeficiency syndrome of the dwarf mouse. Clin Exp Immunol 1971;9:227-240.
39. Duquesnoy R: Immunodeficiency of the thymus-dependent system of the Ames dwarf mouse. J Immunol 1972;108:1578-1590.
40. Dumont F, Robert F, Bischoff P: T and B lymphocytes in pituitary dwarf Snell-Bagg mice. Immunology 1979;38:23-31.
41. Cross R, Bryson J, Roszman T: Immunological disparity in the hypopituitary dwarf mouse. J Immunol 1992;148:1347-1352.
42. Murphy W, Durum S, Longo D: Role of neuroendocrine hormones in murine T cell development. Growth hormone exerts thymopoietic effects in vivo. J Immunol 1992;149:3851-3857.
43. Murphy W, Durum S, Longo D: Differential effects of growth hormone and prolactin on murine T cell development and function. J Exp Med 1993;178:231-236.
44. Kelley K, Brief S, Westly H, Novakofski J, Bechtel P, Simon J, Walker E: GH3 pituitary adenoma cells can reverse thymic aging in rats. Proc Natl Acad Sci USA 1986:83:5663-5667.
45. Binz K, Joller P, Froesch P, Binz H, Zapf J, Froesch E: Repopulation of the atrophied thymus in diabetic rats by insulin-like growth factor I. Proc Natl Acad Sci USA 1990;87:3690-3694.
46. Clark R, Strasser J, McCabe S, Robbins K, Jardieu P: Insulin-like growth factor-1 stimulation of lymphopoiesis. J Clin Invest 1993;92:540-548.
47. Gjerset R, Yeargin J, Volkman S, Vila V, Arya J, Haas M: Insulin-like growth factor-I supports proliferation of autocrine thymic lymphoma cells with a pre-T cell phenotype. J Immunol 1990;145:3497-3501.
48. Gupta S, Fikrig S, Noval M: Immunological studies in patients with isolated growth hormone deficiency. Clin Exp Immunol 1983;54: 87-90.
49. Kiess W, Malozowski S, Gelato M, Butenand O, Doerr H, Crisp B, Eisl E, Maluish A, Belohradsky B: Lymphocyte subset distribution and natural killer activity growth hormone deficiency before and during short-term treatment with growth hormone releasing hormone. Clin Immunol Immunopathol 1988;48:85-94.
50. Murphy W, Taub D, Longo D: The huPBL-SCID mouse as a means to examine human immune function in vivo. Semin Immunol 1996:8:233-241.
51. Taub D, Tsarfaty G, Lloyd A, Durum S, Longo D, Murphy W: Growth hormone promotes human T cell adhesion and migration to both human and murine matrix proteins in vitro and directly promotes xenogeneic engraftment. J Clin Invest 1994;94:293-300.
52. Timsit J, Savino W, Safieh B, Chanson P, Gagnerault M-C, Bach J-F, Dardenne M: Growth hormone and insulin-like growth factor-I stimulate hormonal function and proliferation of thymic epithelial cells. J Clin Endocrinol Metab 1992;75:183-188.
53. Dardenne M, Savino W, Gagnerault M-C, Itoh T, Bach J-F: Neuroendocrine control thymic hormonal production. I. Prolactin stimulates in vivo and in vitro the production of thymulin by human and murine thymic epithelial cells. Endocrinology 1989;125:3-12.
54. Connoy L, Alexander D: The role of intracellular signalling pathways regulating thymocyte and Ieukemic T cell apoptosis. Leukemia 1996; 10:1422-1435.
55. Minshall C, Arkins S, Freund G, Kelley K: Requirement for phosphatidyl 3′-kinase to protect hemopoietic progenitors against apoptosis depends upon the extracellular survival factor. J Immunol 1996;156:939-947.
56. Bellussi G, Muccioli G, Ghè C, Di Carlo R: Prolactin binding sites in human erythrocytes and lymphocytes. Life Sci 1987;41:951-959.
57. Russell D, Kibler R, Matrisian L, Larson D, Poulos B, Magun B: Prolactin receptors on human T and B lymphocytes: Antagonism of prolactin binding by cyclosporine. J Immunol 1985;134:3027-3031.
58. Gala R, Shevach E: Identification by analytical flow cytometry of prolactin receptors on immunocompetent cell populations in the mouse. Endocrinology 1993;133:1617-1623.
59. Viselli S, Mastro A: Prolactin receptors are found on heterogeneous subpopulations of rat splenocytes. Endocrinology 1993;132:571-576.
60. Matera L, Muccioli G, Cesano A, Bellussi G, Genazzani E: Prolactin receptors on large granular lymphocytes: Dual regulation by cyclosporine A. Brain Behav Immun 1988;2:1-10.
61. Chambers W, Amoscato A, Smith M, Kenniston T, Herberman R, Appasamy P: Prolactin receptor expression by rat NK cells. Nat Immun 1995;14:145-156.
62. Savino W, Dardenne M: Immune-neuroendocrine interactions. Immunol Today 1995;16: 318-321.
63. Ali S, Pellegrini I, Kelly P: A prolactin-dependent immune cell line (Nb2) expresses a mutant form of prolactin receptor. J Biol Chem 1991;266:20110-20117.
64. Hiestand P, Mekler P, Nordmann R, Grieder A, Permmongkol C: Prolactin as a modulator of lymphocyte responsiveness provides a possible mechanism of action of cyclosporin. Proc Natl Acad Sci USA 1986;83:2599-2603.
65. Arrenbrecht S: Specific binding of growth hormone to thymocytes. Nature 1974;252:255-257.
66. Badolato R, Bond H, Valerio G, Petrella A, Morrone G, Waters M, Venuta S, Tenore A: Differential expression of surface membrane growth hormone receptor on human peripheral blood lymphocytes detected by dual fluorochrome flow cytometry. J Clin Endocrinol Metab 1994;79:984-990.
67. Tapson V, Boni-Schnetzler M, Pilch P, Center D, Berman J: Structural and functional characterization of the human T lymphocyte receptor for insulin-like growth factor I in vitro. J Clin Invest 1988;82:950-957.
68. Gaufo G, Diamond M: Prolactin increases CD4/CD8 cell ratio in thymus-grafted congenitally athymic nude mice. Proc Natl Acad Sci USA 1996;93:4165-4169.
69. Bates L, Grove D, Mastro A: Mechanisms of activation and suppression in rat Nb 2 lymphoma cells: A model for interactions between prolactin and the immune system. Exp Cell Res 1995;218:567-572.
70. Matera L, Cesano A, Bellone G, Oberholtzer E: Modulatory activity of prolactin on the resting and mitogen-induced activity of T, B, and NK lymphocytes. Brain Behav Immun 1992;6: 409-417.
71. Cesano A, Oberholtzer E, Contarini, Geuna M, Bellone G, Matera L: Independent and synergistic effects of interleukin-2 and prolactin on development of T-and NK-derived LAK effectors. Immunopharmacology 1994;28:67-75.
72. Hosokawa Y, Yang M, Kaneko S, Tanaka M, Nakashima K: Prolactin induces switching of T-cell receptor gene expression from a to g in rat Nb2 pre-T lymphoma cells. Biochem Biophys Res Commun 1996;220:958-962.
73. Nagy E, Berczi I, Wren G, Asa S, Kovacs K: Immunomodulation by bromocriptine. Immunopharmacology 1983;6:231-243.
74. Bernton E, Hartmann D, Holaday J: Antibody to mouse prolactin inhibits murine lymphocyte responses to T-cell growth factors (TCGF). J Leukoc Biol 1987;42:335.
75. Clevenger C, Russell D, Appasamy P, Prystowsky M: Regulation of interleukin 2-driven T-lymphocyte proliferation by prolactin. Proc Natl Acad Sci USA 1990;87:6460-6464.
76. Sabharwal P, Glaser R, Lafuse W, Varma S, Liu Q, Arkins S, Kooijman R, Kutz L, Kelley K, Malarkey W: Prolactin synthesized and secreted by human peripheral blood mononuclear cells: An autocrine growth factor for lymphoproliferation. Proc Natl Acad Sci USA 1992;89:7713-7716.
77. Murphy W, Rui H, Longo D: Effects of growth hormone and prolactin immune development and function. Life Sci 1995;57:1-14.
78. Mercola K, Cline M, Golde D: Growth hormone stimulation of normal and leukemic human T-lymphocyte proliferation in vitro. Blood 1981;58:337-340.
79. Postel-Vinay M-C, de Mello Coelho V, Gagnerault M-C, Dardenne M: Growth hormone stimulates the proliferation of activated mouse T lymphocytes. Endocrinology 1997;138:1816-1820.
80. Stephenson J, Lee J, Bailey N, Shepherd A, Melling J: Adjuvant effect of human growth hormone with an inactivated flavivirus vaccine. J Infect Dis 1991;164:188-191.
81. Snow E, Feldbush T, Oaks J: The effect of growth hormone and insulin upon MLC responses and the generation of cytotoxic lymphocytes. J Immunol 1981;126:161-164.
82. Gonzalo J, Mazuchelli R, Mellado M, Frade J, Carrera A, von Kobbe C, Merida I, Martinez AC: Enterotoxin shock protection and deficient T-helper 2 cytokine production in growth hormone transgenic mice. J Immunol 1996;157: 3298-3304.
83. Span J, Pieters G, Smals A, Koopmans P, Kloppenborg P: Number and percentage of NK cells are decreased in growth hormone-deficient adults. Clin Immunol Immunopathol 1996;78:90-92.
84. Matera L, Bellone G, Lebrun J, Kelly P, Hooghe Peters E, Di Celle P, Foa R, Contarini M, Avanzi G, Asnaghi V: Role of prolactin in the in vitro development of interleukin-2-driven anti-tumoural lymphokine-activated killer cells. Immunology 1996;89:619-626.
85. Matera L, Bellone G, Cesano A: Prolactin and the neuroimmune network. Adv Neuroimmunol 1991;1:158-172.
86. Gerli R, Rambotti P, Nicoletti I, Orlandi S, Migliorati G, Riccardi C: Reduced number of natural killer cells in patients with pathological hyperprolactinemia. Clin Exp Immunol 1986; 64:399-406.
87. Matera L, Ciccarelli E, Cesano A, Veglia F, Miola C, Camanni F: Natural killer activity in hyperprolactinemic patients. Immunopharmacology 1989;18:143-146.
88. Provinciali M, Di Stefano G, Stronati S, Raffaeli W, Pari G, Fabris N: Role of prolactin in the modulation of NK and LAK cell activity after short-or long-term morphine administration in neoplastic patients. Int J Immunopharmacol 1996;18:577-586.
89. Provinciali M, Di Stefano G, Muzzioli M, Garzetti G, Ciavattini A, Fabris N: Relationship between 17β-estradiol and prolactin in the regulation of natural killer cell activity during progression of endometriosis. J Endocrinol Invest 1995;18:645-652.
90. Chakraborty A, Chakraborty N, Chattophdhyay U: Prolactin response of NK cells, but not of LAK cells, is deficient in patients with carcinoma of oral cavity and during aging. Int J Cancer 1996;66:65-69.
91. Muzzioli M, Mocchegiani E, Bressani N, Bevilacqua P, Fabris N: In vitro restoration by thymulin of NK actvity of cells from old mice. Int J Immunopharmacol 1992;14:57-61.
92. Chen Y, Johnson A: In vivo activation of macrophages by prolactin from young and aging mice. Int J Immunopharmacol 1993;15:39-45.
93. Edwards C III, Ghiasuddin S, Schepper J, Yunger L, Kelley K: A newly defined property of somatotropin:Priming of macrophages for production of Superoxide anion. Science 1988;239: 769-771.
94. Wiedermann C, Reinisch N, Brausteiner H: Stimulation of monocyte chemotaxis by human growth hormone and its deactivation by somatostatin. Blood 1993;82:954-960.
95. Di Carlo R, Meli R, Galdiero M, Nuzzo I, Bentivoglio C, Romano Carratelli C: Prolactin protection against lethal effects of Salmonella typhimurium. Life Sci 1993;53:981-989.
96. Edwards C III, Yunger L, Lorence R, Dantzer R, Kelley K: The pituitary gland is required for protection against lethal effects of Salmonella typhimurium. Proc Natl Acad Sci USA 1991; 88:2274-2277.
97. Haeffner A, Thieblemont N, Déas O, Marelli O, Charpentier B, Senik A, Wright S, Haeffner-Cavaillon N, Hirsch F: Inhibitory effect of growth hormone on TNF-α secretion and nuclear factor-κB translocation in lipopolysaccharide-stimulated human monocytes. J Immunol 1997;158:1310-1314.
98. Benedetto N, Folgere A, Galdiero M, Meli R, Di Carlo R: Effect of prolactin, rIFN-γ or rTNF-α in murine toxoplasmosis. Pathol Biol 1995;43:395-400.
99. Zellweger R, Zhu X-H, Wichmann M, Ayala A, DeMaso C, Chaudry I: Prolactin administration following hemorrhagic shock improves mortality from subsequent sepsis. J Immunol 1996;157:5748-5754.
100. Zhu X-H, Zellweger R, Wichmann M, Ayala A, Chaudry I: Effects of prolactin and metoclopramide on macrophage gene expression in late sepsis. Cytokine 1977;9:437-446.
101. Bernton E, Meltzer M, Holaday J: Suppression of macrophage activation and T-lymphocyte function in hypoprolactinemic mice. Science 1988;239:401-404.